What are the possible side effects of Evinopon 1.5%?
Get emergency medical help if you have signs of an allergic reaction to Evinopon 1.5%: sneezing, runny or stuffy nose; wheezing or trouble breathing; hives; swelling of your face, lips, tongue, or throat.
Get emergency medical help if you have signs of a heart attack or stroke: chest pain spreading to your jaw or shoulder, sudden numbness or weakness on one side of the body, slurred speech, feeling short of breath.
Stop using Evinopon 1.5% and call your doctor at once if you have:
the first sign of any skin rash, no matter how mild;
shortness of breath (even with mild exertion);
swelling or rapid weight gain;
signs of stomach bleeding - bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
liver problems - nausea, upper stomach pain, itching, tired feeling, flu-like symptoms, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
kidney problems - little or no urinating, painful or difficult urination, swelling in your feet or ankles, feeling tired or short of breath;
high blood pressure - severe headache, pounding in your neck or ears, nosebleed, anxiety, confusion;
low red blood cells (anemia) - pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating; or
severe skin reaction - fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.
Common Evinopon 1.5% side effects may include:
indigestion, gas, stomach pain, nausea, vomiting;
headache, dizziness, drowsiness;
itching, increased sweating;
increased blood pressure; or
swelling or pain in your arms or legs.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Side effects of Evinopon 1.5% in details
A side effect of any drug can be defined as the unwanted or undesired effect produced by the drug. The side effect can be major or in few medications minor that can be ignored. Side effects not only vary from drug to drug, but it also depends on the dose of the drug, the individual sensitivity of the person, brand or company which manufactures it. If side effects overweigh the actual effect of the medicine, it may be difficult to convince the patient to take the drug. Few patients get specific side effects to specific drugs; in that case, a doctor replaces the drug with another. If you feel any side effect and it troubles you, do not forget to share with your healthcare practitioner.
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
Cardiovascular Thrombotic Events
GI Bleeding, Ulceration and Perforation
Heart Failure and Edema
Renal Toxicity and Hyperkalemia
Serious Skin Reactions
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of a single dose of Evinopon 1.5% was evaluated in 2 placebo-controlled trials with a total of 634 migraine patients treated with Evinopon 1.5% for a single migraine headache. Following treatment with Evinopon 1.5% potassium (either Evinopon 1.5% or Evinopon 1.5% potassium immediate-release tablets [as a control]), 5 subjects (0.8%) withdrew from the studies; following placebo exposure, 1 subject (0.2%) withdrew.
The most common adverse reactions (i.e., that occurred in 1% or more of Evinopon 1.5%-treated patients) and more frequent with Evinopon 1.5% than with placebo were nausea and dizziness.
Table 1: Adverse Reactions With Incidence > 1% and Greater Than Placebo in Studies 1 and 2 Combined
The most common adverse events resulting in discontinuation of patients following Evinopon 1.5% dosing in controlled clinical trials were urticaria (0.2%) and flushing (0.2%). No withdrawals were due to a serious reaction.
The following adverse reactions have been identified during post approval use of Evinopon 1.5% or other NSAIDs. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse Reactions Reported With Evinopon 1.5% And Other NSAIDs
In patients taking Evinopon 1.5% or other NSAIDs, the most frequently reported adverse reactions occurring in approximately 1%-10% of patients are: GI reactions (including abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, GI ulcers [gastric/duodenal], and vomiting), abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritus, rashes, and tinnitus.
Additional adverse reactions reported in patients taking NSAIDs include occasionally:
Special Senses: Conjunctivitis, hearing impairment
What is the most important information I should know about Evinopon 1.5%?
Evinopon 1.5% patch may cause dizziness or drowsiness. Theses effects may be worse if you take it with alcohol or certain medicines. Use Evinopon 1.5% patch with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.
Evinopon 1.5% patch is for use on the skin only. Do not get it in your eyes, nose, or mouth. If you get Evinopon 1.5% patch in your eye, wash the eye out with water or saline right away. Contact your doctor if irritation persists for more than 1 hour.
Do NOT use more than 1 patch at a time or use Evinopon 1.5% patch for longer than prescribed without checking with your doctor.
If irritation occurs at the application site, remove the patch and contact your doctor.
Serious stomach ulcers or bleeding can occur with the use of Evinopon 1.5% patch. Taking it in high doses or for a long time, smoking, or drinking alcohol increases the risk of these side effects. Taking Evinopon 1.5% patch with food will NOT reduce the risk of these effects. Contact your doctor or emergency room at once if you develop severe stomach or back pain; black, tarry stools; vomit that looks like blood or coffee grounds; or unusual weight gain or swelling.
Evinopon 1.5% patch is an NSAID. Before you start any new medicine, check the label to see if it has an NSAID (eg, ibuprofen) in it too. If it does or if you are not sure, check with your doctor or pharmacist.
Do not take aspirin while you are using Evinopon 1.5% patch unless your doctor tells you to.
Lab tests, including kidney and liver function, blood electrolyte levels, complete blood cell counts, and blood pressure, may be performed while you use Evinopon 1.5% patch. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.
Use Evinopon 1.5% patch with caution in the ELDERLY; they may be more sensitive to its effects, especially stomach bleeding and kidney problems.
Evinopon 1.5% patch should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.
PREGNANCY and BREAST-FEEDING: Evinopon 1.5% patch may cause harm to the fetus. Do not use it during the last 3 months of pregnancy. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Evinopon 1.5% patch while you are pregnant. It is not known if Evinopon 1.5% patch is found in breast milk. Do not breast-feed while using Evinopon 1.5% patch.
Evinopon 1.5% contraindications
Contraindication can be described as a special circumstance or a disease or a condition wherein you are not supposed to use the drug or undergo particular treatment as it can harm the patient; at times, it can be dangerous and life threatening as well. When a procedure should not be combined with other procedure or when a medicine cannot be taken with another medicine, it is called Relative contraindication. Contraindications should be taken seriously as they are based on the relative clinical experience of health care providers or from proven research findings.
Hypersensitivity to Evinopon 1.5% sodium or to any of the excipients of Evinopon 1.5%.
Active gastric or intestinal ulcer, bleeding or perforation.
Last trimester of pregnancy.
Hepatic, renal and severe cardiac failure.
Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid and/or other drugs with prostaglandin-synthetase inhibitory activity.
Treatment of peri-operative pain in setting of coronary artery bypass graft (CABG) surgery.
The use of high dose Evinopon 1.5% (150 mg/day) for >4 weeks is contraindicated in patients with established cardiovascular disease (congestive heart failure, established ischemic heart disease, peripheral arterial disease) or uncontrolled hypertension.
Established Cardiovascular Disease or Significant Cardiovascular Risk Factors: The use of high dose Evinopon 1.5% (150mg/day) for >4 weeks is contraindicated in patients with established cardiovascular disease (congestive heart failure, established ischemic heart disease, peripheral arterial disease) or uncontrolled hypertension. If Evinopon 1.5% treatment is needed, patients with established cardiovascular disease, uncontrolled hypertension or significant cardiovascular risk factors (eg, hypertension, hyperlipidaemia, diabetes mellitus and smoking) should be treated only after careful consideration and at doses ≤100 mg daily if the treatment is for >4 weeks. As the cardiovascular risks of Evinopon 1.5% may increase with dose and duration of exposure, Evinopon 1.5% should always be prescribed at the lowest effective daily dose and for the shortest duration possible.
Renal Impairment: Evinopon 1.5% is contraindicated in patients with renal failure. No specific studies have been carried out in patients with renal impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering Evinopon 1.5% to patients with mild to moderate renal impairment.
Hepatic Impairment: Evinopon 1.5% is contraindicated in patients with hepatic failure. No specific studies have been carried out in patients with hepatic impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering Evinopon 1.5% to patients with mild to moderate hepatic impairment.
DailyMed. "DICLOFENAC EPOLAMINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
European Chemicals Agency - ECHA. "Diclofenac: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Evinopon 1.5% are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Evinopon 1.5%. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported side effects
No survey data has been collected yet
There are no reviews yet. Be the first to write one!